These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11696586)

  • 41. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.
    Astolfi A; Rolla S; Nanni P; Quaglino E; De Giovanni C; Iezzi M; Musiani P; Forni G; Lollini PL; Cavallo F; Calogero RA
    Cancer Immunol Immunother; 2005 Jun; 54(6):599-610. PubMed ID: 15690207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.
    Cifaldi L; Quaglino E; Di Carlo E; Musiani P; Spadaro M; Lollini PL; Wolf S; Boggio K; Forni G; Cavallo F
    Cancer Res; 2001 Apr; 61(7):2809-12. PubMed ID: 11306448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
    Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody.
    Pilon SA; Piechocki MP; Wei WZ
    J Immunol; 2001 Sep; 167(6):3201-6. PubMed ID: 11544306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
    Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
    J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
    Steel JC; Ramlogan CA; Yu P; Sakai Y; Forni G; Waldmann TA; Morris JC
    Cancer Res; 2010 Feb; 70(3):1072-81. PubMed ID: 20086176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
    Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
    Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice.
    Boggio K; Di Carlo E; Rovero S; Cavallo F; Quaglino E; Lollini PL; Nanni P; Nicoletti G; Wolf S; Musiani P; Forni G
    Cancer Res; 2000 Jan; 60(2):359-64. PubMed ID: 10667588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
    Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice.
    Curcio C; Khan AS; Amici A; Spadaro M; Quaglino E; Cavallo F; Forni G; Draghia-Akli R
    Cancer Gene Ther; 2008 Feb; 15(2):108-14. PubMed ID: 17992201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity.
    Spadaro M; Ambrosino E; Iezzi M; Di Carlo E; Sacchetti P; Curcio C; Amici A; Wei WZ; Musiani P; Lollini PL; Cavallo F; Forni G
    Clin Cancer Res; 2005 Mar; 11(5):1941-52. PubMed ID: 15756020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.
    Quaglino E; Iezzi M; Mastini C; Amici A; Pericle F; Di Carlo E; Pupa SM; De Giovanni C; Spadaro M; Curcio C; Lollini PL; Musiani P; Forni G; Cavallo F
    Cancer Res; 2004 Apr; 64(8):2858-64. PubMed ID: 15087404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
    Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
    Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.